6ŒŽ30“úi“yj | 
									
									
										  | 
										Opening Remarks | 
									
									
										 | 
										 | 
									
									
										 | 
										 | 
										“¡àV@—²•v | 
										2007”N“xŒ¤‹†‰ï ‰ï’·^ 
i“Æj‘—§•a‰@‹@\ŽOd•a‰@ —Õ°Œ¤‹†•” | 
									
									
										 
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										  | 
										Session 1 | 
									
									
										 | 
										À@’· | 
										ŽRŒû@³—Y | 
										“Œ‹ž‘åŠwˆãŠw•”•‘®•a‰@ ƒAƒŒƒ‹ƒM[ƒŠƒEƒ}ƒ`“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										1-1 | 
										ŽÀŒ±“Iƒ}ƒEƒXS‹Ø‰Š‚̉ŠÇ×–EZ‚É‚¨‚¯‚éJanus kinaseiJAKj‚Ì–ðŠ„ | 
									
									
										 | 
										 | 
										 | 
										•½àV@«’j | 
										‘åãˆã‰È‘åŠw ‘æ3“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										1-2 | 
										OAŠ´ìƒ‚ƒ‹ƒ‚ƒbƒg‚Ì‹CŠÇ‚É‚¨‚¯‚éƒoƒjƒƒCƒhŽó—e‘̂ɂ‚¢‚Ä | 
									
									
										 | 
										 | 
										 | 
										“nç³@’¼l | 
										¹ƒ}ƒŠƒAƒ“ƒiˆã‰È‘åŠw ŒÄ‹zŠíEŠ´õÇ“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										1-3 | 
										šb‘§ƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éConserved noncoding sequence 1iCNS-1j‚̉ðÍ | 
									
									
										 | 
										 | 
										 | 
										ŠŽR —Yˆê˜Y | 
										i“Æj‘—§•a‰@‹@\ ‘Š–ÍŒ´•a‰@ —Õ°Œ¤‹†ƒZƒ“ƒ^[ | 
									
										 | 
										 | 
									
										 
										 | 
										 | 
										 | 
										 | 
										 | 
									
										  | 
										Session 2 | 
									
									
										 | 
										À@’· | 
										‰Á“¡@•F | 
										ŒQ”nŒ§‰q¶ŠÂ‹«Œ¤‹†Š | 
									
									
										 | 
										 | 
									
									
										 | 
										2-1 | 
										ƒqƒg––½ŒŒT×–E‚É‚¨‚¯‚éTh1/Th2•ª‰»‚Ì•sŠ®‘S«‚Æ‚»‚Ì—vˆö | 
									
									
										 | 
										 | 
										 | 
										_À@@C | 
										“Œ‹ž“s—Õ°ˆãŠw‘‡Œ¤‹†Š ‰Ô•²ÇƒvƒƒWƒFƒNƒg | 
									
									
										 | 
										 | 
									
									
										 | 
										2-2 | 
										ƒqƒXƒgƒ“’EƒAƒZƒ`ƒ‹‰»y‘f‘jŠQ–ò‚É‚æ‚é FIP1L1-PDGFRƒ¿Œ¸‹@˜‚̉ðÍ | 
									
									
										 | 
										 | 
										 | 
										ÎŒ´@Œ¤Ž¡ | 
										“Œ–k‘åŠw ‘åŠw‰@–òŠwŒ¤‹†‰È ‹@”\•ªŽq¶‰»Šw•ª–ì | 
									
									
										 | 
										 | 
									
									
										 | 
										2-3 | 
										‹CŠÇŽxšb‘§‚É‚¨‚¯‚éDŽ_‹…‹@”\‚ɑ΂·‚éHGF‚ÌŒø‰Ê | 
									
									
										 | 
										 | 
										 | 
										ˆÉ“¡@@˜j | 
										H“c‘åŠw ˆãŠw•” —Õ°ŒŸ¸ˆãŠw | 
									
									
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										 
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										  | 
										Session 3 | 
									
									
										 | 
										À@’· | 
										‘å‹v•Û Šì—Y | 
										ˆã—Ö@lm—Y‰ï •ä‚•a‰@ | 
									
									
										 | 
										 | 
									
									
										 | 
										3-1 | 
										ŒŒŠÇ“à”ç×–E‚ÌDŽ_‹…Ú’…—U“±”\‚É‚¨‚æ‚Ú‚·IFN-ƒ¿/ƒÀ‚Ìì—p | 
									
									
										 | 
										 | 
										 | 
										¬—Ñ@ˆÐm | 
										é‹Êˆã‰È‘åŠw ŒÄ‹zŠí“à‰È | 
									
									
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										 | 
										 | 
									
									
										 | 
										3-2 | 
										Budesonide/formoterol‚ÍŠˆ«‰»DŽ_‹…‚ÌÚ’…”\‚ðCü‚µ‚È‚¢‚ªAŠˆ«‰»—U“±Œã’PŠj‹…‚ÌIL-5ARANTESATNF-ƒ¿ŽY¶‚ð—}§‚·‚é | 
									
									
										 | 
										 | 
										 | 
										ž[@@’ms | 
										é‹Êˆã‰È‘åŠw‘‡ˆã—ÃZƒ“ƒ^[ ŒÄ‹zŠí“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										3-3 | 
										ƒAƒŒƒ‹ƒM[«‰ŠÇ‚É‚¨‚¯‚éPPARƒÁ‚ÌDŽ_‹…Ú’…”\§Œä | 
									
										 | 
										 | 
										 | 
										ç—t@‹Ml | 
										H“c‘åŠw ˆãŠw•” —Õ°ŒŸ¸ˆãŠw | 
									
										 | 
										 | 
										 | 
										 | 
										 | 
									
										 
										 | 
										 | 
									
										 | 
										 | 
										 | 
										 | 
										 | 
									
										  | 
										Session 4 | 
									
									
										 | 
										À@’· | 
										‰i“c@@^ | 
										é‹Êˆã‰È‘åŠwˆãŠw•” ŒÄ‹zŠí“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										4-1 | 
										D’†‹…—R—ˆƒvƒƒeƒA[ƒ[‚É‚æ‚éDŽ_‹…‚ÌŠˆ«‰» | 
									
									
										 | 
										 | 
										 | 
										–ìŠÔ@áŽq | 
										i“Æj‘—§•a‰@‹@\ŽOd•a‰@ —Õ°Œ¤‹†•” | 
									
									
										 | 
										 | 
									
									
										 | 
										4-2 | 
										DŽ_‹…‹@”\‚É‚¨‚¯‚éƒzƒXƒzƒŠƒp[ƒ[C‚Ì–ðŠ„ | 
									
									
										 | 
										 | 
										 | 
										²–ì ˆÀŠóŽq | 
										‹ß‹E‘åŠw ˆãŠw•” ŒÄ‹zŠíEƒAƒŒƒ‹ƒM[“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										4-3 | 
										Interferon-ƒÁ‚ÍTh2ƒTƒCƒgƒJƒCƒ“‚É‚æ‚éDŽ_‹…‚Ì×–E“àƒVƒOƒiƒ‹•ªŽq‚ÌƒŠƒ“Ž_‰»‚ð˜´i‚·‚é | 
									
									
										 | 
										 | 
										 | 
										ŽRŒû@‹MŽj | 
										ŒQ”nŒ§‰q¶ŠÂ‹«Œ¤‹†Š | 
									
										 | 
										 | 
									
										 
										 | 
										 | 
										 | 
										 | 
										 | 
									
										  | 
										Session 5 | 
									
									
										 | 
										À@’· | 
										‘å–ì@@ŒM | 
										“Œ –k–ò‰È‘åŠw •a‘Ô¶—Šw‹³Žº | 
									
									
										 | 
										 | 
									
									
										 | 
										5-1 | 
										IL-5ˆâ“`Žq“±“ü‚ÍDŽ_‹…‘‘½‚ð—U“±‚µA‚»‚ÌŒã‚ÌRŒ´“ÁˆÙ“I–Ɖu‰ž“š‚ð—}§‚·‚é | 
									
									
										 | 
										 | 
										 | 
										’†ž@ˆê”V | 
										“Œ‹ž‘åŠw ˆãŠw•” ƒAƒŒƒ‹ƒM[EƒŠƒEƒ}ƒ`“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										5-2 | 
										TAT-PTEN×–E“à“±“ü‚É‚æ‚éDŽ_‹…¶‘¶‚Æ—V‘–‚Ì—}§@ | 
									
									
										 | 
										 | 
										 | 
										‘«—§@“N–ç | 
										’鋞‘åŠw ˆãŠw•” “à‰ÈŠwuÀ | 
									
									
										 | 
										 | 
									
									
										 | 
										5-3 | 
										DŽ_‹…«è÷—±’`”’Major basic proteiniMBPj‚ÍRespiratory syncytial virusiRSVj‚É‚æ‚é‹C“¹ã”ç×–E‚̃Aƒ|ƒg[ƒVƒX‚¨‚æ‚Ñ‹C“¹‰ŠÇ‚ð‘‹‚·‚é | 
									
									
										 | 
										 | 
										 | 
										Ήª@‘å¬ | 
										ŒQ”nŒ§‰q¶ŠÂ‹«Œ¤‹†Š | 
									
									
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										 | 
										 | 
									
									
										 | 
										5-4 | 
										ƒqƒgD‰–Šî‹…‚ÌFas‚ð‰î‚µ‚½Apoptosis‚Ì—U“±‚ɂ‚¢‚Ä | 
									
									
										 | 
										 | 
										 | 
										¼–{@Œ’Ž¡ | 
										‘—§¬ˆçˆã—ÃZƒ“ƒ^[Œ¤‹†Š –ƉuƒAƒŒƒ‹ƒM[Œ¤‹†•” | 
									
									
										 
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										  | 
										Session 6 | 
									
									
										 | 
										À@’· | 
										Ö“¡@”Ž‹v | 
										‘—§¬ˆçˆã—ÃZƒ“ƒ^[Œ¤‹†Š –ƉuƒAƒŒƒ‹ƒM[Œ¤‹†•” | 
									
									
										 | 
										 | 
									
									
										 | 
										6-1 | 
										^‹ÛRŒ´‚É‚æ‚é‹C“¹ã”ç×–E‚ÌMUC5AC‚Ì”Œ» | 
									
									
										 | 
										 | 
										 | 
										¬ŒF@@„ | 
										Œcœä‹`m‘åŠw ˆãŠw•” ŒÄ‹zŠí“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										6-2 | 
										ƒqƒg‹CŠÇŽx•½ŠŠ‹Ø×–E‚̕”|—{ƒRƒ‰[ƒQƒ“ƒQƒ‹‚ð—p‚¢‚½ŽûkŽÀŒ±Œn‚ÌŠm—§ | 
									
									
										 | 
										 | 
										 | 
										–k‘º@‹IŽq | 
										i“Æj‘—§•a‰@‹@\ ‘Š–ÍŒ´•a‰@ —Õ°Œ¤‹†ƒZƒ“ƒ^[ | 
									
									
										 | 
										 | 
									
									
										 | 
										6-3 | 
										¸_“IƒXƒgƒŒƒX—U”«šb‘§‚É‚¨‚¯‚é’†•_ŒoŒnƒÊ-ƒIƒsƒIƒCƒhŽó—e‘̂̊֗^‚ƖƉu‰ž“šCü | 
									
									
										 | 
										 | 
										 | 
										‰œŽR@D | 
										“Œ–k–ò‰È‘åŠw •a‘Ô¶—Šw‹³Žº | 
									
									
										 
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										  | 
										Session 7 | 
									
									
										 | 
										À@’· | 
										“Œ“c@—L’q | 
										‹ß‹E‘åŠwˆãŠw•”•‘®•a‰@ ŒÄ‹zŠíEƒAƒŒƒ‹ƒM[“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										7-1 | 
										ƒXƒM‹}‘¬–Ɖu—Ö@‚É‚æ‚éD‰–Šî‹…CD203c”Œ»•ω»‚ÌŒŸ“¢ | 
									
									
										 | 
										 | 
										 | 
										’·”ö ‚݂Â٠| 
										i“Æj‘—§•a‰@‹@\ ŽOd•a‰@ —Õ°Œ¤‹†•” | 
									
									
										 | 
										 | 
									
									
										 | 
										7-2 | 
										ƒXƒMŒ¸Š´ì—Ö@‚É‚¨‚¯‚錌´’†blocking antibody‚ÉŠÖ‚·‚é‹@”\‰ðÍ | 
									
									
										 | 
										 | 
										 | 
										ìã@ˆ»Žq | 
										“Œ‹ž‘åŠw ˆãŠw•” ƒAƒŒƒ‹ƒM[EƒŠƒEƒ}ƒ`“à‰È | 
									
									
										 | 
										 | 
									
									
										 | 
										7-3 | 
										ƒXƒ^ƒ`ƒ“‚͔얞זE‚©‚ç‚̃TƒCƒgƒJƒCƒ“ŽY¶‚ð—}§‚·‚é | 
									
									
										 | 
										 | 
										 | 
										‰ÁX”ü Vˆê˜Y | 
										ç—t‘åŠw ‘åŠw‰@ˆãŠwŒ¤‹†‰@ ˆâ“`Žq§ŒäŠw | 
									
									
										 
										 | 
										 | 
										 | 
										 | 
										 | 
									
  | 
Session 8 | 
 | 
À@’· | 
X@@»•v | 
i“Æj‘—§•a‰@‹@\‘Š–ÍŒ´•a‰@ 
—Õ°Œ¤‹†ƒZƒ“ƒ^[ æ’[‹ZpŠJ”Œ¤‹†•” | 
 | 
 | 
 | 
8-1 | 
‹CŠÇŽxšb‘§Š³ŽÒ‚Ì––½ŒŒ‚¨‚æ‚ьċC‹Ãk‰t‚ð—p‚¢‚½Ž_‰»ƒXƒgƒŒƒX•]‰¿ | 
 | 
 | 
 | 
—é–Ø T‘¾˜Y | 
º˜a‘åŠw ˆãŠw•” ‘æˆê“à‰È | 
 | 
 | 
 | 
8-2 | 
Churg-Strauss syndromeiCSSj‚Ì•a‘ÔŒ`¬‚ւ̧Œä«T×–E‚ÌŠÖ—^‰¿ | 
 | 
 | 
 | 
âV“¡@”ŽŽm | 
i“Æj‘—§•a‰@‹@\ ‘Š–ÍŒ´•a‰@ —Õ°Œ¤‹†ƒZƒ“ƒ^[ | 
 | 
 | 
 | 
8-3 | 
DŽ_‹…«•›•@o‰Š‚Ì—\Œã’²¸|ŽèpŒã5”N‚ÌŒo‰ßŠÏŽ@‚©‚ç| | 
 | 
 | 
 | 
¼˜e@—R“T | 
“Œ‹žŽœŒb‰ïˆã‰È‘åŠw ˆãŠw•” ލ•@ˆôA‰ÈŠw‹³Žº | 
 
 | 
 | 
 | 
 | 
 | 
										  | 
										Closing Remarks | 
									
									
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										 | 
										 | 
										 | 
										 | 
										 | 
									
									
										  | 
										  | 
										  | 
										  | 
										  |